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drainage of the bronchus. For this reason, 0.5 ml fibrin 
glue was administered in our case. In the following 6 
months, although radiotherapy was applied to the 
area, no relapse was observed and this reflected the 
reliability of the procedure. 
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Dear Editor 
Chemoprophylaxis for tuberculosis 
Dr Israel’s sensitive and sensible editorial on 
chemoprophylaxis for tuberculosis (Respiratory 
Medicine, February 1993) sounds caution with regard 
to isoniazid (INH) and opens questions that we have 
been considering for some time. Although the oft- 
quoted American evidence suggests that a short 
course of INH considerably reduces cases of clinically 
manifest disease over the 2 years following known 
contact with an infectious index case, the frequently 
drawn conclusion that this is evidence of bacterial per- 
sistors being destroyed must be questioned. The cases 
prevented are likely to be those in an early stage of 
development of disease due to exogenous infection in 
persons in whom persistor bacilli have not become 
established. There is no reason to think that INH can 
prevent cases arising from endogenous activation, 
except during the time that the drug is being taken. 
If this is so, then a short course of INH in persons 
co-infected with HIV may prove disappointing. 
Persistor status is a balance between the propensity 
of the tubercle bacillus to multiply and cause disease, 
and the ability of T helper cell mediated immunity to 
hold the organisms in stasis (1). We know that this 
balance tips in favour of the bacillus very early in HIV 
infection, apparently being one of the earliest immune 
functions lost. On theoretical grounds, arming the 
immune system to destroy bacilli already in stasis 
should be an option for prophylaxis potentially just as 
effective in persons infected with drug resistant bacilli 
as in those infected with drug susceptible organisms. 
Sadly, we know BCG not to be capable of this, but 
progress need not end there. Although we have no 
more than fragmentary evidence that it can actually be 
done, investigations into the action of immunotherapy 
with Mycobacterium waccae for clinical tuberculosis 
suggest that the mechanisms induced should also be 
active in destroying persistor tubercle bacilli before 
they give rise to disease. Studies have already started to 
evaluate this possibility in close contacts of tubercu- 
losis patients and may soon be applied to tuberculin 
positive HIV seropositive patients. 
The studies upon which this proposition is based are 
just beginning to appear in the literature, and the 
evidence in support of the value of immunotherapy in 
the treatment of pulmonary tuberculosis, both drug- 
resistant and susceptible, is growing almost daily. 
Studies are completed, or in progress in Kuwait (2), 
Gambia (3), Iran (4), Nigeria (5), Romania and 
Vietnam, and anecdotal evidence on small numbers of 
cases has been received from Sweden, India and the 
U.K. 
The mechanism of its action appears to be an 
enhancement of recognition of common mycobacterial 
antigens, together with a switch in T cell function from 
the equivalent of THY to THY. Work in progress 
suggests that this switch involves changes in the 
cytokine-endocrine axis, which modulate the subsets of 
helper T cells generated in response to mycobacterial 
antigens. 
Enhanced THY activity would be precisely what is 
needed to hold bacilli in persistance, or even to lead to 
their true elimination. The lack of toxicity or deleterious 
side effects of autoclaved M. vaccae (NCTC 11659) are 
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likely to make it infinitely safer than INH chemo- 
prophylaxis, and, dare we suggest it, infinitely more 
successful. 
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Dear Editor 
Lung cancer in young patients of South India 
The article by Capewell et al. (1) prompts me to 
share our experience and compare the results of 
bronchogenic carcinoma in the young (2) from a rural 
tertiary care teaching hospital of South India. Both the 
articles being contemporary, I would like to highlight 
the similarities and dissimilarities in findings of both 
the studies. In our study, we have arbitrarily taken the 
age of 40 years as the cut off year as have previous 
authors (3-5), and found the incidence to be as high as 
10.8% (2) i.e. 50 cases out of total 539 lung cancer 
patients studied between January 1987 to December 
1989. It is to be emphasized that, unlike in Scotland 
where lung cancer is the most common cancer among 
men and women, in India cancer of the oropharyngeal 
region, and cancer of the cervix are the commonest 
ones among men and women, respectively (6). The 
probable high incidence of lung cancer in young 
Indians may be partly explained on the basis of low life 
expectancy and high smoking habit, particularly bidis 
(rolled tendu leaves with tobacco) and cigarettes with- 
out filters. However, in contrast to the Scottish study, 
we found small cell cancer of the lung to be 24% (vs. 
34%) squamous cell carcinoma 24% (vs. 23%) and 
adenocarcinoma 10% (vs. 20%). The remaining 
patients were histopathologically either anaplastic or 
poorly differentiated type. 
The high incidence of small cell cancer of lung in the 
young, in two ethnically different population cor- 
roborates the facts of genetic predisposition and rapid 
growth rate in this particular type of lung cancer, as 
quoted by the authors. Since the majority of the 
patients had presented with pleural effusion or pneu- 
monia (stage III) prognosis was poor and no different 
from older patients with this disease. 
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Dear Editor 
Spontaneous intrapleural rupture of mediastinal 
teratoma ~ Ashour M, Hawass El-Din, Adam KAR, 
Joharjy I. Respir Med 1993; 87: 69-72 
These authors present an interesting complication 
of a benign mediastinal germ cell tumour. Whilst the 
X-ray certainly indicates an effusion, a cynic must ask 
whether rupture was indeed spontaneous. Looking at 
the subsequent CT scan it would have been extremely 
difficult to avoid intubating the cyst and this would 
account for all the biochemical findings at surgery. 
It is not uncommon to find an effusion in relation- 
ship to such a cyst but in my experience this is not 
related to rupture but caused by the intense inflam- 
matory reaction which surrounds such cysts and which 
